MIA shines in poster session
22 November 2019
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
PhD student Grace Attrill presented her work on possible biomarkers of response in Stage III melanoma patients treated with anti-PD-1 immunotherapy. She has found that a specific population of immune cell appears in higher numbers in patients who were treated with anti-PD-1 and did not recur. Her research also found that another subpopulation of immune cells may be associated with increased risk of melanoma recurrence. Grace’s poster notes that these immune cells could be a possible biomarker that may indicate which patients will respond well to immunotherapy.
Recent PhD graduate Dr Tuba Nur Gide, also presented a poster on immune cells in melanoma patients treated with immunotherapy. Dr Gide looked at the distribution of specific immune cells in relation to patient response. She found a significant association between response to immunotherapy and a very short distance between immune cells and melanoma cells. A higher amount of these immune cells that were close to patient melanoma cells also related to better progression-free survival for patients on immunotherapy. These findings could also be used to create better biomarkers of patient response.
Another PhD student, Jarem Edwards, presented his research on tumour mutation burden as a possible factor in patient survival. He found that the number of mutations in a patient’s melanoma was not predictive of the amount of immune cells, nor did they predict response or survival in melanoma patients.
Finally, medical oncology fellow, Dr Lalit Pallan, presented his poster on clinical predictors of outcome in melanoma patients with brain metastases treated with combination immunotherapy. Clinicopathological characteristics of patients are those that can be observed by clinicians through minimally invasive techniques such as scans and blood tests. Dr Pallan found that levels of LDH (an enzyme regularly tested for in the blood of melanoma patients), the number of brain metastases, and prior treatments may be factors that could help clinicians determine the likely outcome of treatment. Notably, patients with a lower burden of brain metastases that are asymptomatic and are treated for the first time with combination immunotherapy are more likely to respond to their treatment and have longer progression-free and overall survival.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.